Your session is about to expire
← Back to Search
Ustekinumab for Psoriasis
Study Summary
This trial is looking to see if researchers can predict which psoriasis drugs will work for individual patients by looking at markers or gene patterns. Participants will try two different drugs for 8 weeks at a time and have their skin monitored for improvement.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 43 Patients • NCT02187172Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My insurance covers Stelara and either Tremfya or Skyrizi.I have been diagnosed with plaque-type psoriasis by a skin specialist or through a biopsy.I have never been treated with ustekinumab, guselkumab, or risankizumab.At least 10% of my skin is affected by my condition.I have psoriatic arthritis or another similar condition like Crohn's disease.You haven't used tanning booths for at least 4 weeks before the study starts.I cannot get ustekinumab, gusekumab, or risankizumab for the trial.I have been using skin treatments like steroids or Vitamin D on my lesions for at least 2 weeks.I have been on systemic or biologic therapy for at least 8 weeks.
- Group 1: Treatment
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still openings for participants in this scientific experiment?
"As per the updated data hosted on clinicaltrials.gov, this medical trial is no longer recruiting patients. The study was initially posted in December 1st 2022 and recently modified on October 19th of 2022. Nevertheless, there are 167 other trials looking for participants at this moment."
Has the U.S. Food and Drug Administration officially certified Ustekinumab for human use?
"There is ample evidence from Phase 4 trials confirming Ustekinumab's safety; accordingly, it was scored 3 out of 3."
Is the population for this investigation limited to individuals who are under forty years old?
"This research is inviting participants aged between 18 years and 89 years to take part."
To which individuals is this research open?
"This trial is currently seeking 56 individuals aged 18 to 89 years old with a diagnosis of psoriasis. Candidates must possess an insurance plan that covers anti-P40 and P19 biologics, have not previously used ustekinumab, guselkumab, or risankizumab, present at least 10% body surface area involvement in their condition as seen by board-certified dermatologist/dermatology nurse practitioner/skin punch biopsy, and accept the terms outlined in the informed consent document reviewed by IRB approval procedures."
Share this study with friends
Copy Link
Messenger